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Abstract
INTRODUCTION—There is limited understanding of relationships between genotype, phenotype 
and other conditions contributing to health in neonates with medium-chain acyl-coenzyme A 
dehydrogenase deficiency (MCADD) identified through newborn screening.
METHODS—Retrospective analysis of comprehensive data from a cohort of 221 newborn-
screened subjects identified as affected with MCADD in the Inborn Errors of Metabolism – 
Information System (IBEM-IS), a long term follow-up database of the Inborn Errors of 
Metabolism Collaborative, was performed.
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RESULTS—The average age at notification of first newborn screen results to primary care or 
metabolic providers was 7.45 days. The average octanoylcarnitine (C8) value on first newborn 
screen was 11.2 umol/L (median 8.6, range 0.36–43.91). A higher C8 level correlated with an 
earlier first subspecialty visit. Subjects with low birth weight had significantly lower C8 values. 
Significantly higher C8 values were found in symptomatic newborns, in newborns with abnormal 
lab testing in addition to newborn screening and/or diagnostic tests, and in subjects homozygous 
for the c.985A>G ACADM gene mutation or compound heterozygous for the c.985A>G mutation 
and deletions or other known highly deleterious mutations. Subjects with neonatal symptoms, or 
neonatal abnormal labs, or neonatal triggers were more likely to have at least one copy of the 
severe c.985A>G ACADM gene mutation. C8 and genotype category were significant predictors 
of the likelihood of having neonatal symptoms. Neonates with select triggers were more likely to 
have symptoms and laboratory abnormalities.
CONCLUSIONS—This collaborative study is the first in the United States to describe health 
associations of a large cohort of newborn-screened neonates identified as affected with MCADD. 
The IBEM-IS has utility as a platform to better understand the characteristics of individuals with 
newborn-screened conditions and their follow-up interactions with the health system.
Keywords
medium-chain acyl-coenzyme A dehydrogenase deficiency; MCAD; octanoylcarnitine; ACADM; 
newborn screening; inborn error of metabolism
1. INTRODUCTION
Medium-chain acyl-coenzyme A dehydrogenase deficiency (MCADD) is an autosomal 
recessive mitochondrial fatty acid oxidation disorder. A recent report on the birth prevalence 
of disorders detectable through newborn bloodspot screening noted an overall MCADD birth 
prevalence of 5.3 (4.1–6.7, 99% CI) per 100,000 births across a variety of racial/ethnic 
groups (1). Impaired hepatic ketogenesis resulting in hypoketotic hypoglycemia, metabolic 
acidosis, liver disease, and lethargy can rapidly progress to coma and death when glycogen 
stores are depleted during catabolic physiological states (2). Undiagnosed, morbidity and 
mortality are considerable, but when the diagnosis is known, MCADD can be successfully 
managed and outcomes improved (3). Early detection of affected infants is important (4). 
Thus, MCADD is a core condition on the U.S. Department of Health and Human Services 
Advisory Committee on Heritable Disorders in Newborns and Children’s Recommended 
Uniform Screening Panel and newborn screening for this condition is done in all 50 U.S. 
states, the District of Colombia and Puerto Rico (5) (6). Despite an acknowledgement that 
this condition can have a significant health impact in early life, limited understanding exists 
of the complex interplay between genotype, biochemical phenotype, and other conditions 
associated with health outcomes of neonates with MCADD.
Accumulation of the medium-chain acylcarnitine species is characteristic of MCADD, with 
octanoylcarnitine (C8) as the prominent blood marker (7). Higher C8 values in blood spot 
newborn screening have been reported in association with homozygosity for the common c.
985A>G pathogenic gene variant (8), or the presence of other severe pathogenic variants 
such as deletion, nonsense, or splice site mutations in the ACADM gene (9). Higher blood 
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spot C8 values have also been reported in MCADD affected neonates, particularly those 
homozygous for the c.985A>G mutation, whose blood spots were collected sooner after 
birth (10).
This is the first multi-state, multi-center collaborative study in the United States to describe 
associations between newborn screen C8 values, ACADM genotype, clinical circumstances 
and symptoms, and clinical laboratory abnormalities in a large cohort of newborn-screened 
neonates identified as affected with MCADD.
Using data submitted by the Inborn Errors of Metabolism Collaborative, this study sought to 
learn if first newborn screen C8 values are related to gender, genotype, birth weight, or 
initial food source. We investigated whether C8 values are associated with the presence of 
neonatal triggers, the presence of neonatal symptoms, and the presence of neonatal abnormal 
lab results in addition to newborn screening or diagnostic tests. We also assessed if the 
presence of neonatal triggers is associated with the manifestation of neonatal symptoms and 
abnormal neonatal labs. We examined if there are correlations between first newborn screen 
C8 value and birth weight, and days of age at the first subspecialist visit, and if potential 
correlations between C8 value and the days of age at the first subspecialist visit differ 
between subjects with and without neonatal triggers, with and without neonatal symptoms, 
with and without neonatal abnormal labs. Finally, we sought associations between ACADM 
genotype and neonatal triggers, neonatal symptoms, and neonatal abnormal labs and 




The research protocol was approved by the Institutional Review Boards of the Inborn Errors 
of Metabolism Collaborative (IBEMC) partners and informed consent was documented in 
the Inborn Errors of Metabolism – Information System (IBEM-IS) for all enrolled MCADD 
subjects (11) (12). The IBEMC data collection began in 2007 and is currently managed 
using REDCap electronic data capture tools hosted at the Michigan Public Health Institute 
(MPHI) (13).
Data for this study were extracted from the IBEM-IS on August 7, 2015. The inclusion 
criteria for this study were subjects having: 1) consented for data-sharing, 2) assignment of 
the condition MCADD, 3) abnormal newborn screening result, and 4) a first newborn screen 
C8 value. Newborn screen MCADD-related acylcarnitine values other than C8 were not 
included in this study due to insufficient data collection on those values in the IBEM-IS. 
Blood spot collection timing was unavailable for most subjects.
2.2. VARIABLES
The IBEM-IS defines the neonatal period as the first 28 days of life. It does not require 
specification of whether recorded neonatal complications, symptoms and abnormal labs are 
clinically determined to be caused by or related to MCADD. For this analysis, we 
reclassified the documented neonatal complications, symptoms and abnormal labs into three 
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types: 1) neonatal triggers, 2) neonatal symptoms, and 3) neonatal abnormal labs, and 
defined “neonatal” as those that were known to have occurred within the first 28 days of life. 
Neonatal triggers were defined as neonatal complications and interventions suggestive of 
underlying health complications determined by clinician authors as most likely to result in 
potential MCADD symptoms. Neonatal symptoms were defined by clinician authors as 
symptoms consistent with MCADD, many based on reports of symptoms manifested in 
individuals affected with MCADD (9) (14) (15) (16) (17) (18) (19) (20). Neonatal abnormal 
labs were defined by clinician authors as laboratory test abnormalities of potential concern 
in the context of MCADD (excluding newborn screening and MCADD diagnostic 
biochemical and molecular test results). The IBEM-IS data did not allow for determination 
of whether jaundice and hyperbilirubinemia during the neonatal period reflected physiologic 
versus pathogenic newborn conditions. To avoid possible over-estimation of the neonatal 
symptoms/abnormal labs classified as associated with MCADD, we excluded jaundice/
hyperbilirubinemia from the analyses. Birth weight was treated both as a continuous variable 
and was also categorized as low birth weight (<=2.5 kg), or not. The source of neonatal 
nutrition was categorized as breastfed only, or not. Age at first visit, age at notification, and 
age at intervention are age of days since birth until the subject was first seen by a 
subspecialist, the subject’s primary care or metabolic provider was first notified of the 
newborn screening results, and the intervention for MCADD was initiated, respectively. C8 
is the octanoylcarnitine value, measured in umol/L, on the first newborn screen.
To analyze genotype, alleles were categorized based on documented ACADM gene allele 
findings (Table 5). The categories were as follows: A) the c.985A>G mutation (21) (22), B) 
ACADM deletions, and mutations other than c.985A>G for which reports of decreased fatty 
acid oxidation in fibroblast studies or considerably decreased MCAD enzyme activity were 
found in published literature (23) (24) (25) (26) (27) (28) (29), C) all other allele findings 
not meeting criteria for A or B (4) (23) (25) (29) (30) (31) (32) (33) (34) (35), and D) empty 
or indecipherable entries in the allele data fields, as data are entered as free text. The dataset 
contained eight combinations of two alleles: AA (n=69), AB (n=18), BB (n=1), AC (n=49), 
AD (n=26), CC (n=12), CD (n=2), and DD (n=44). The BB group contained too few cases 
to compute stable statistics and was excluded from genotype analysis. The AD, CD, and DD 
groups were also excluded from analysis due to the lack of usable genotype information. 
The remaining four genotype categories were further collapsed into two categories for 
selected additional analyses as follows: 1) AA and AB, and 2) AC and CC.
2.3 STATISTICAL ANALYSES
The Mann-Whitney U test was used to assess differences in C8 values between each pair of 
groups, defined by: low birth weight or not, breastfed only or not, presence or absence of 
neonatal triggers, presence or absence of neonatal symptoms, presence or absence of 
neonatal abnormal labs, and the two collapsed genotype categories. The Kruskal-Wallis test 
was used to compare C8 values among the four genotype categories. Correlations between 
C8, birth weight and age at first visit were tested using the Spearman correlation test. Chi-
square tests were used to test the associations between categorical variables.
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To further examine whether the strength of the relationship between C8 and age at first visit 
differs between each pair of subgroups defined by, presence or absence of neonatal triggers, 
presence or absence of neonatal symptoms, and presence or absence of neonatal abnormal 
labs, we constructed three generalized linear models (negative binomial with log link 
function). In each model, age at first visit was the dependent variable, C8 and one of the 
above three binary variables, along with the interaction term, were the independent 
variables.
Logistic regression with neonatal symptoms as the binary outcome variable, and the 
collapsed genotype category, C8, and gender as predictors, was conducted to determine 
whether these variables predict the likelihood of developing neonatal symptoms.
All statistical significance tests were two-sided. Bonferroni correction was used to adjust for 
multiple comparisons to keep the overall significance level at α=0.05. All the statistical 
analyses were conducted in IBM SPSS Statistics for Windows, Version 23.0.
3. RESULTS
A total of 337 consented subjects were assigned the condition MCADD, 285 (85%) of 
whom had abnormal newborn screening. Of the 285 subjects, 223 had a first newborn screen 
C8 value documented in the IBEM-IS. Two subjects with first newborn screen C8 values 
presumed to be erroneously recorded (2406 umol/L and 1738 umol/L) were excluded. The 
remaining 221 subjects, all identified in the IBEM-IS as alive at the time of data extraction, 
constituted the dataset for this study.
Age of subjects at IBEMC enrollment ranged from infancy to 10 years (n=218). Average 
reported birth weight was 3.35 kg (n=213, Std. Dev.=0.53). Subjects’ first newborn screen 
C8 value averaged 11.2 umol/L (median=8.6, range 0.36–43.91, Std. Dev.=10.12). MCADD 
diagnostic testing was documented to be done for the majority of subjects in this cohort 
(Table 1).
Eligibility for enrollment in the IBEMC is dependent upon the individual having been given 
a diagnosis of an inborn error of metabolism, in this case, MCADD. Diagnostic methods and 
results were documented in the IBEM-IS for the majority of subjects with MCADD included 
in this study (Table 2).
The majority of subjects had at least one clinical biochemical diagnostic laboratory test 
abnormality and/or two ACADM allele findings recorded in the IBEM-IS (N=189, 86%). 
Among the five subjects with normal biochemical diagnostic testing recorded, three had two 
ACADM allele findings, with genotype categories AA, CC, and CC. The two CC subjects 
had normal plasma acylcarnitine profiles, the AA subject had normal urine organic acids, 
and additional biochemical diagnostic testing results were not recorded for these three 
subjects. The remaining two subjects had one allele finding, both with normal urine organic 
acids and without other biochemical diagnostic testing results recorded.
Subjects’ average age at notification of the first abnormal newborn screen to a primary care 
or metabolic provider was 7.45 days (n=191, Std. Dev.=19.44). Average age since birth to 
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initiation of intervention for MCADD was 8.11 days (n=197, Std. Dev.=19.41). Subjects 
averaged 16.77 days of age at the time of the first subspecialist visit (n=202, Std. 
Dev.=22.27).
The types and frequencies of select neonatal clinical characteristics and laboratory 
abnormalities in our dataset are summarized in Table 3.
C8 values and age at first visit were negatively correlated (p = 0.001, Spearman’s rho = 
−0.227) indicating subjects seen by subspecialists sooner had higher C8 levels. Generalized 
linear regression results confirmed the negative correlation; for every one unit increase in 
C8, age at first visit decreased by 2% (p < 0.001). While the correlation was stronger (more 
negative) in subjects who had neonatal symptoms or neonatal abnormal labs than for 
subjects who did not, the difference in the magnitude of the correlation was not statistically 
significant.
There was no difference in C8 values between males and females (mean rank=112 vs. 110, 
p=0.76), nor between breastfed-only subjects and those whose neonatal diet contained other 
types of nutrition such as formula, total parenteral nutrition, and/or intralipids, plus or minus 
breast milk (mean rank=90 vs. 84, p=0.43). Subjects with birth weight less than or equal to 
2.5 kg had significantly lower C8 values than the rest (mean rank=73 vs. 109, p=0.04). 
Significantly higher C8 values were found in subjects with neonatal symptoms (mean 
rank=114 vs. 86, p=0.008), and in subjects with neonatal abnormal labs (mean rank=59 vs. 
41, p=0.003). There was no significant difference in C8 values between subjects with and 
without neonatal triggers (mean rank=107 vs. 98, p=0.388) (Table 4), although subjects with 
neonatal triggers were more likely to have neonatal symptoms and neonatal abnormal labs 
(p<0.001 in both tests, results not shown).
C8 values significantly differed among the four genotype categories (p<0.001). Post hoc 
pairwise comparisons showed C8 values significantly higher in the AA genotype group than 
in the AC (adjusted p<0.001) and CC (adjusted p=0.001) groups; and C8 values significantly 
higher in the AB genotype group than in the AC group (adjusted p=0.046). Although the 
data suggested a difference in C8 values between the AB genotype and the CC genotype 
groups, the test failed to reach statistical significance (adjusted p=0.144), which may be due 
to low power. C8 values were significantly higher in the AA&AB group than in the AC&CC 
group (p<0.001). Figure 1 shows the mean, median, and rank of C8 value for the four-
category and two-category genotype variables.
For subjects with recorded and decipherable ACADM allele findings in the IBEM-IS, the c.
985A>G mutation was most frequently appearing. The c.199T>C allele was the next most 
frequently appearing, with twelve subjects compound heterozygous for this allele and the c.
985A>G mutation, and two subjects heterozygous for this allele and two other C type 
alleles. Subjects with the c.985A>G/c.199T>C genotype had first newborn screen C8 values 
ranging from 1.28–5.43 umol/L) and either no or unknown triggers, symptoms or abnormal 
labs in the first 28 days of life. The other two subjects with the c.199T>C/other C type 
genotype had first newborn screen C8 values of ≤0.6 umol/L, and had no triggers, symptoms 
or abnormal labs in the first 28 days of life.
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Additionally, the proportions of subjects with genotype category AA or AB were 
significantly higher in subjects who had neonatal symptoms, neonatal abnormal labs, or 
neonatal triggers than the proportions in subjects recorded as asymptomatic (91% vs 52%, 
p=0.001, Phi=0.298)., without abnormal labs (88% vs 58%, p=0.032, Phi=0.275),, or 
without triggers during neonatal period (81% vs 55%, p=0.009, Phi=0.227). Further analysis 
demonstrated that both the two-category genotype variable and C8 were significant 
predictors of the likelihood of having neonatal symptoms. For every one unit increase in C8 
value, the odds of having neonatal symptoms increased by 6% (p=0.016, EXP(B)=1.06). 
The odds of having neonatal symptoms in subjects with AA or AB genotype was 4.93 times 
of that in subjects with AC, or CC (p=0.050, EXP(B)=4.93).
4. CONCLUSIONS
This collaborative study is the first in the United States to describe health associations of a 
large cohort of newborn-screened neonates with MCADD. The IBEM-IS platform was 
designed to allow examination of complex associations between newborn screening results, 
clinical conditions and laboratory findings of individuals with inborn errors of metabolism. 
The IBEM-IS data increases our understanding of interactions with public health and 
clinical systems related to the notification and follow-up of abnormal newborn screening 
results for children with rare inborn errors of metabolism. The opportunity to examine a 
large cohort of newborn screened individuals with MCADD expands understanding of 
factors associated with their health in the first 28 days of life.
In 2014, the Society of Inherited Metabolic Disorders identified MCADD as one of several 
critical conditions requiring immediate notification of the health care provider upon 
ascertainment of an abnormal newborn screening result (36). Recently, the Advisory 
Committee on Heritable Disorders in Newborns and Children recommended that 
presumptive positive screening results for time-critical conditions be immediately reported 
to the child’s health care provider and by no later than 5 days of life (37). Our subjects had a 
longer documented mean age (7.45 days) at the time of newborn screen result notification 
indicating that improvement in timely notification must remain a priority to minimize risks 
of symptom initiation in these vulnerable newborns. Initiation of MCADD intervention 
occurred at a mean age of 8 days in our cohort. The close proximity in time of notification 
and intervention reflects the priority of clinicians to intervene in the care of newborns with 
possible MCADD as soon as possible.
In an attempt to determine if poor initiation of breast-feeding might be a risk factor for 
neonates with this condition, we specifically queried whether the diet of the neonates was 
associated with C8 values. Despite the failure to observe an association between high C8 
values and exclusive breast-feeding in this data analysis, neonates who are exclusively 
breast-fed and in whom initiation of feeding is problematic may well be at additional risk for 
decompensation. Our observations cannot rule out poor breastfeeding initiation as a risk 
factor without additional information about this specific issue.
C8 values >0.3 umol/L along with additional results of MCADD-related ratios have been 
considered by some as indicative of MCADD by neonatal screening (20) (38). A worldwide 
Bentler et al. Page 7













collaborative project looking at the clinical validation of the cutoff target range of C8 in 
tandem mass spectrometry newborn screening describes disorder ranges for acylcarnitines 
and related ratios in MCADD, creating a tool for assessing screening results (39). Although 
all subjects in our cohort had a first newborn screen C8 value ≥0.36 umol/L, data available 
did not uniformly include additional newborn screening acylcarnitine values or ratios, 
preventing inclusion in our data analysis. The significant associations we found between the 
first newborn screen C8 value and low birth weight, symptoms, and clinical lab 
abnormalities for neonates with MCADD highlight the importance of providing quantitative 
screening result data to clinicians caring for children with abnormal newborn screen results 
for MCADD. Clinicians receiving such results should view very high C8 values as a signal 
for increased concern for symptomatic presentation of the condition.
Overrepresentation of infants with flagged newborn screening acylcarnitine values among 
infants in neonatal intensive care or with very low birth weight has been reported (10). 
Distribution of blood spot C8 concentrations did not vary greatly by birth weight in another 
study (40). In our study, neonates with MCADD in the low birth weight (<=2.5 kg) group 
had significantly lower C8 values. Although some of our low birth weight subjects had 
neonatal triggers, most had neither neonatal symptoms nor neonatal abnormal labs, and 7 out 
of 13 were homozygous for the c.985A>G ACADM mutation. These findings suggest that 
low birth weight itself may be a factor associated with lower newborn screen C8 values than 
might otherwise be expected given risk factors such as a deleterious genotype. The relative 
lower C8 values in this group may be due to these babies with low birth weight already 
receiving medical care with adequate prevention of fasting to prevent MCADD-associated 
complications causing elevations of C8. Data collection regarding the timing of first 
newborn screen sampling was a relatively recent addition to the IBEM-IS. Therefore, data 
on age at first newborn screen bloodspot collection was unavailable for most of our subjects. 
This is an important limitation to the conclusions of our study, given the findings of others 
regarding the relationship of C8 values and age at sample timing for infants with MCADD, 
as previously noted (10).
Our findings support the work of others demonstrating significant associations between 
higher C8 newborn screen values and homozygosity for the c.985A>G mutation as well as 
higher C8 newborn screen values in the presence of other severe ACADM mutations. 
Conservative categorization of B genotype alleles may have influenced our results. Some C 
genotype alleles may be more deleterious than currently categorized, solely supported by our 
literature search, a strategy chosen to minimize the risk that our conclusions overemphasize 
the association between deleterious mutations and increasing C8 values.
Although this study includes information about a very large number of children with 
MCADD, there are important limitations in considering our conclusions. This cohort does 
not represent the full denominator of newborn-screened children diagnosed with MCADD in 
the catchment area of the participating IBEMC centers. Study limitations include the 
potential for selection bias in subject enrollment. We also accepted the premise that all 
subjects assigned the condition MCADD in the IBEM-IS are truly affected, and most but not 
all subjects in this study had IBEM-IS documentation of at least one biochemical diagnostic 
testing abnormality and/or two ACADM allele findings. While the IBEM-IS does not 
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mandate documentation of the rationale for individual diagnostic testing decisions and 
practices, we note that of the 10% of subjects with ACADM molecular testing recorded as 
“not done” at the time of data extraction, all are minors and all had MCADD biochemical 
diagnostic testing performed. Over half of them had at least one biochemical diagnostic 
testing abnormality recorded, and the remainder of those subjects had wide ranging (0.50–
28.84 umol/L) first newborn screen C8 values but no MCADD biochemical diagnostic 
testing results documented in the IBEM-IS. Finally, though the data collection tools were 
designed to primarily elicit fixed responses, rare fields require free-text responses (for 
example, genotype) and few fields obligate data entry, yielding the potential for partial or 
otherwise inaccurate entry of information. There is also the potential for data entry errors in 
the IBEM-IS.
Additional work by the IBEMC is needed to further clarify and understand the significance 
of the 30 additional different ACADM alleles documented in the IBEM-IS for which 
published literature referencing the finding was not found. Such work ultimately may or may 
not support the genotype allele categorization strategy used in this study, and could 
potentially improve understanding of genotype-phenotype correlations. Importantly, this 
cohort of newborn-screened subjects allows for the observation of longer-term health 
outcomes for individuals with MCADD identified early in life.
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• Retrospective analysis of 221 newborn-screened subjects with MCAD 
deficiency (76)
• NBS C8 and genotype were significant predictors of having neonatal 
symptoms (75)
• Symptomatic neonates were more likely to have at least one copy of 
985A>G mutation (82)
• Neonates with select triggers were more likely to have symptoms (64)
• The IBEM-IS is a platform to better understand newborn-screened 
conditions (74)
Bentler et al. Page 13














C8 comparisons by genotype category
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Table 1




Age (in years) at IBEMC enrollment
  < 1 100 45%
  1–2 55 25%
  3–5 39 18%
  6–10 24 11%
  Missing 3 1.4%
Race
  American Indian or Alaska Native 0 0%
  Asian 1 0.5%
  Black or African American 6 2.7%
  Native Hawaiian or Other Pacific Islander 0 0%
  White 189 86%
  Two or More Races 3 1.4%
  Not Reported or Unknown 22 10%
Ethnicity
  Hispanic or Latino 14 6%
  Not Hispanic or Latino 191 86%
  Not Reported or Unknown 16 7%
Gender
  Male 117 53%
  Female 104 47%
Biochemical diagnostic testing for MCADD
  Any testing
   Done 202 91%
   Not done 2 1%
  Plasma acylcarnitine profile
   Done 166 75%
    Abnormal 161 97%
    Within normal limits 4 2%
  Urine organic acids
   Done 109 49%
    Abnormal 82 75%
    Within normal limits 20 18%
  Urine acylglycine profile
   Done 16 7%
    Abnormal 15 94%
    Within normal limits 1 6%
  Enzyme assay
   Done 0 0%

















  Fatty acid oxidation probe assay
   Done 5 2%
    Abnormal 5 100%
Genetic (DNA) testing for MCADD
  Done 186 84%
  Not done 21 10%
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Table 3
Type and frequency of neonatal triggers, neonatal symptoms, and neonatal abnormal labs
Neonatal Triggers, Symptoms and Abnormal Labs Frequency of Appearance
aNeonatal Triggers (37 subjects)
  Poor Feeding 20
  Prematurity (<37 weeks gestation) 15
  Antibiotics 12
  Respiratory distress 7
  Infection/sepsis 5
  Dehydration 4
  Failure to thrive 2
  Fever 2
  Intralipids 2
  Transient Tachypnea of the Newborn 2
  Decreased oxygen saturation, fasted, loose stools, mild gastroesophageal reflux, poor growth, poor latch, 
vomiting, gavage feeding
1 each
bNeonatal Symptoms (28 subjects)
  Lethargy 13
  Distress 9
  Tachypnea 8
  Hypoglycemia 5
  Hypothermia 3
  Hypotonia 3
  Irritability 3
  Cardiomyopathy 2
  Sleepy 2
  Apnea, hepatomegaly, limp, metabolic acidosis, Echo: mild left hypertrophy, pallor, seizure, sweaty, 
tachycardia, temperature instability
1 each
cNeonatal Abnormal Labs (21 subjects)
  Hypoglycemia 20
  Elevated liver function tests 7
  Metabolic acidosis 6
  Elevated uric acid 3
  Low Co2 2
  Hyperuricemia 2
  Elevated C reactive protein, abnormal carnitine level, abnormal CMP, elevated BUN, elevated CK, elevated 
creatinine, hyperammonemia, ketonuria, slight elevation ALT
1 each
a
neonatal complications and interventions suggestive of underlying health complications in the data determined by clinician authors as most likely 
to result in potential MCADD symptoms.
b
neonatal symptoms in the data determined by clinician authors as consistent with MCADD, many based on reports of symptoms manifested in 
individuals affected with MCADD. IBEM-IS data entry does not require clinician specification of whether a subject’s symptoms were ultimately 
attributed to or related to the particular IBEM diagnosis.
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c
neonatal laboratory test abnormalities in the data determined by clinician authors to be of potential concern in the context of MCADD (excluding 
newborn screening and MCADD diagnostic biochemical and molecular test results).
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Table 4
Comparison of the first newborn screen C8 value by select characteristics
Factor Mean C8 Median C8 Std. Dev. From Mean Mean Rank
Gender
  Female (n=104) 10.15 8.32 8.25 109.61
  Male (n=117) 12.13 8.69 11.48 112.24
Breastfed Only
  Yes (n=97) 12.16 10.28 10.24 89.66
  No (n=76) 10.96 8.24 10.36 83.61
Low Birthweight
  Yes (n=13) 7.51 2.85 10.54 73
  No (n=200) 11.58 8.93 10.07 109.21
Neonatal Triggers
  Yes (n=37) 13.24 11.7 11.80 106.84
  No (n=161) 11.00 8.6 9.77 97.81
Neonatal Symptoms
  Yes (n=28) 16.32 13.35 11.99 114.36
  No (n=152) 10.48 8.37 9.62 86.11
Neonatal Abnormal Labs
  Yes (n=21) 18.46 14.93 12.42 59.45
  No (n=68) 10.12 8.32 9.45 40.54
Genotype (Four Categories)
  AA (n=69) 15.76 13.36 10.76 96.00
  AB (n=18) 11.89 11.00 10.24 80.72
  AC (n=49) 5.73 3.65 6.51 49.24
  CC (n=12) 4.63 3.37 4.31 44.67
Genotype (Two Categories)
  AA&AB (n=87) 14.96 13.30 10.71 92.84
  AC&CC (n=61) 6.83 3.72 6.13 48.34
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Table 5
aDifferent ACADM allele findings of the 221 study subjects
Allele Genotype Category Assigned Reference
bc.985A>G (p.K329E or p.K304E) A (21) (22)
c.233T>C B (23) (24)
c.1102_1105delTTAG B (25) (26)
c.734C>T(p.S245L) B (23) (25)
c.1238G>A (p.R413H) B (25)
c.928G>A B (23)
c.362 C>T B (23) (27)
c.347G>A B (28)
cc.799G>A B  (29)
N=2 additional different deletions, not found by published literature search, were recorded in 
the IBEM-IS
B
c.127 G>A (p.E43K) C (25)
c.797A>G C (25)
c.1207A>G C (25)








dc.199T>C (Y67H; Y42H) C (23)
c.387+1delG C  (30)
c.157C>T C  (32)
c.583G>A C  (33)
c.728G>A C  (4)
c.617G>T (p.R206L) C  (30)
c.447 G>A C  (29) (34)
c.250C>T (p.L84F) C  (25)
c.92G>A C  (35)
N=28 additional different allele findings, not found by published literature search, were 
recorded in the IBEM-IS
C
a
Excludes subjects with empty and indecipherable entries in the allele data fields (genotype category D)
b
Frequency of genotype category A allele is 231
c
Most frequently appearing genotype category B allele (n=6)
d
Most frequently appearing genotype category C allele (n=14).
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